You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Article info

Article menu

Download PDFPDF

XML
Research Article
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Authors

  • Menno Tamminga Department of Pulmonary DiseasesUniversity of Groningen, University Medical Center Groningen Hanzeplein 1, P.O. Box 30.0001 9700 Groningen RB The Netherlands PubMed articlesGoogle scholar articles
  • Sanne de Wit Department of Medical Cell BioPhysics, Faculty of Sciences and TechnologyUniversity of Twente Enschede The Netherlands PubMed articlesGoogle scholar articles
  • T. Jeroen N. Hiltermann Department of Pulmonary DiseasesUniversity of Groningen, University Medical Center Groningen Hanzeplein 1, P.O. Box 30.0001 9700 Groningen RB The Netherlands PubMed articlesGoogle scholar articles
  • Wim Timens Department of Pathology and Medical BiologyUniversity of Groningen, University Medical Center Groningen Groningen The Netherlands PubMed articlesGoogle scholar articles
  • Ed Schuuring Department of Pathology and Medical BiologyUniversity of Groningen, University Medical Center Groningen Groningen The Netherlands PubMed articlesGoogle scholar articles
  • Leon W. M. M. Terstappen Department of Medical Cell BioPhysics, Faculty of Sciences and TechnologyUniversity of Twente Enschede The Netherlands PubMed articlesGoogle scholar articles
  • Harry J. M. Groen Department of Pulmonary DiseasesUniversity of Groningen, University Medical Center Groningen Hanzeplein 1, P.O. Box 30.0001 9700 Groningen RB The Netherlands PubMed articlesGoogle scholar articles
  1. ↵a 0031503616161 m.tamminga{at}umcg.nl
View Full Text

Citation

Tamminga M, de Wit S, Hiltermann TJN, et al
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
Journal for ImmunoTherapy of Cancer 2019;7:173. doi: 10.1186/s40425-019-0649-2

Publication history

  • Received March 7, 2019
  • Accepted June 21, 2019
  • First published July 10, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.